For U.S. Residents Only
+|Aa|-

Indication for Renvela and Renagel

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Important Safety Information for Renvela and Renagel

  • Sevelamer is contraindicated in patients with bowel obstruction.

Click here for additional Important Safety Information.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Renassist

Having trouble with Renvela prescription coverage? Renassist® may be able to help. Learn more

Access to your medication

Sanofi Renal is committed to helping you get access to our medications. We have a range of programs and services designed to help.

  • Renassist® may be able to help if you are having trouble with Renvela® prescription coverage.
  • Other assistance programs may be available to help you get the treatment you need.
  • Restrictions may apply to certain programs.

Learn more by calling 1-800-847-0069 or visiting Renassist.com.

Indication for Renvela and Renagel

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

Important Safety Information for Renvela and Renagel

  • Sevelamer is contraindicated in patients with bowel obstruction.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel (sevelamer hydrochloride) or Renvela® (sevelamer carbonate) tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela® (sevelamer carbonate) suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

The health information contained herein is provided for general education purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.